Literature DB >> 12424066

Tamoxifen non-compliance: does it matter?

Vedang Murthy1, Geeta Bharia, Rajiv Sarin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12424066     DOI： 10.1016/s1470-2045(02)00895-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  15 in total

1.  Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women.

Authors:  Kathryn E Weaver; Fabian Camacho; Wenke Hwang; Roger Anderson; Gretchen Kimmick
Journal:  Am J Clin Oncol       Date:  2013-04       Impact factor: 2.339

2.  Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer.

Authors:  Catherine M Bender; Amanda L Gentry; Adam M Brufsky; Frances E Casillo; Susan M Cohen; Meredith M Dailey; Heidi S Donovan; Jacqueline Dunbar-Jacob; Rachel C Jankowitz; Margaret Q Rosenzweig; Paula R Sherwood; Susan M Sereika
Journal:  Oncol Nurs Forum       Date:  2014-05       Impact factor: 2.172

3.  Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial.

Authors:  Stephanie R Land; Walter M Cronin; D Lawrence Wickerham; Joseph P Costantino; Nicholas J Christian; William M P Klein; Patricia A Ganz
Journal:  Cancer Prev Res (Phila)       Date:  2011-08-23

4.  Patient adherence to aromatase inhibitor treatment in the adjuvant setting.

Authors:  S Verma; Y Madarnas; S Sehdev; G Martin; J Bajcar
Journal:  Curr Oncol       Date:  2011-05       Impact factor: 3.677

5.  Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1.

Authors:  Stephanie R Land; Farzana L Walcott; Qing Liu; D Lawrence Wickerham; Joseph P Costantino; Patricia A Ganz
Journal:  J Natl Cancer Inst       Date:  2015-11-27       Impact factor: 13.506

Review 6.  Oral antineoplastic agents: how do we care about adherence?

Authors:  Marie Barillet; Virginie Prevost; Florence Joly; Bénédicte Clarisse
Journal:  Br J Clin Pharmacol       Date:  2015-10-28       Impact factor: 4.335

7.  Adjuvant hormonal therapy use among insured, low-income women with breast cancer.

Authors:  Gretchen Kimmick; Roger Anderson; Fabian Camacho; Monali Bhosle; Wenke Hwang; Rajesh Balkrishnan
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

8.  Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer.

Authors:  C McCowan; J Shearer; P T Donnan; J A Dewar; M Crilly; A M Thompson; T P Fahey
Journal:  Br J Cancer       Date:  2008-11-04       Impact factor: 7.640

9.  Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain.

Authors:  R Font; J A Espinas; M Gil-Gil; A Barnadas; B Ojeda; I Tusquets; M A Segui; M Margelí; A Arcusa; A Prat; M Garcia; J M Borras
Journal:  Br J Cancer       Date:  2012-09-06       Impact factor: 7.640

10.  Adherence evaluation of endocrine treatment in breast cancer: methodological aspects.

Authors:  Anne S Oberguggenberger; Monika Sztankay; Beate Beer; Birthe Schubert; Verena Meraner; Herbert Oberacher; Georg Kemmler; Johannes Giesinger; Eva Gamper; Barbara Sperner-Unterweger; Christian Marth; Bernhard Holzner; Michael Hubalek
Journal:  BMC Cancer       Date:  2012-10-15       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.